Obesity, dieting, and weight cycling are common among reproductive-age women. Weight cycling refers to intentional weight loss followed by unintentional weight regain. Weight loss is accompanied by changes in gut peptides, adipose hormones, and energy expenditure that promote weight regain to a tightly regulated set point. While weight loss can improve body composition and surrogate markers of cardiometabolic health, it is hypothesized that the weight regain can result in an overshoot effect, resulting in excess weight gain, altered body composition, and negative effects on surrogate markers of cardiometabolic health. Numerous observational studies have examined the association of weight cycling and health outcomes. There appears to be modest association between weight cycling with type 2 diabetes mellitus and dyslipidemia in women, but no association with hypertension, cardiovascular events, and overall cancer risk. Interestingly, mild weight cycling may be associated with a decreased risk of overall and cardiovascular mortality. Little is known about the effects of weight cycling in the preconception period. Although obesity and weight gain are associated with pregnancy complications, preconception weight loss does not appear to mitigate the risk of most pregnancy complications related to obesity. Research on preconception weight cycling may provide insight into this paradox.
{"title":"Weight Cycling in Women: Adaptation or Risk?","authors":"Katelyn J Carey, Wendy Vitek","doi":"10.1055/s-0040-1721418","DOIUrl":"https://doi.org/10.1055/s-0040-1721418","url":null,"abstract":"<p><p>Obesity, dieting, and weight cycling are common among reproductive-age women. Weight cycling refers to intentional weight loss followed by unintentional weight regain. Weight loss is accompanied by changes in gut peptides, adipose hormones, and energy expenditure that promote weight regain to a tightly regulated set point. While weight loss can improve body composition and surrogate markers of cardiometabolic health, it is hypothesized that the weight regain can result in an overshoot effect, resulting in excess weight gain, altered body composition, and negative effects on surrogate markers of cardiometabolic health. Numerous observational studies have examined the association of weight cycling and health outcomes. There appears to be modest association between weight cycling with type 2 diabetes mellitus and dyslipidemia in women, but no association with hypertension, cardiovascular events, and overall cancer risk. Interestingly, mild weight cycling may be associated with a decreased risk of overall and cardiovascular mortality. Little is known about the effects of weight cycling in the preconception period. Although obesity and weight gain are associated with pregnancy complications, preconception weight loss does not appear to mitigate the risk of most pregnancy complications related to obesity. Research on preconception weight cycling may provide insight into this paradox.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"40 5-06","pages":"277-282"},"PeriodicalIF":2.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-0040-1721418","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9247650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karin Brandell, John J Reynolds-Wright, Clare Boerma, Gillian Gibson, Helena Hognert, Heera Tuladhar, Oskari Heikinheimo, Sharon Cameron, Kristina Gemzell-Danielsson
"Very early medical abortion" (VEMA) refers to medical abortion (with mifepristone and misoprostol) before intrauterine pregnancy is visualized on ultrasound. Our aim is to present the current evidence on efficacy, safety (focused on ectopic pregnancies), and how to assess treatment success of VEMA. We conducted a systematic review of studies reporting outcomes of VEMA. The field is small and so our objective was to map all relevant literature, without conducting meta-analysis. We searched PubMed, Medline, and Embase on April 19, 2022. We conducted a narrative synthesis of the evidence. A total of 373 articles were identified. Six articles (representing four observational and one pilot trial) were included in the final review. Across all included studies, treatment efficacy ranged between 91 and 100%. Prevalence of ectopic pregnancy was low and very few cases (n = 2) of ruptures were reported. Most studies used serial serum human chorionic gonadotrophin (s-hCG) levels to determine success of abortion; one study used low sensitivity urine hCG. From the available evidence, VEMA appears to be efficacious and does not appear to cause harm to ectopic pregnancies. Treatment can be assessed with pre- and postabortion s-hCG. Good quality, randomized controlled trial evidence is needed to best inform practice.
{"title":"Medical Abortion before Confirmed Intrauterine Pregnancy: A Systematic Review.","authors":"Karin Brandell, John J Reynolds-Wright, Clare Boerma, Gillian Gibson, Helena Hognert, Heera Tuladhar, Oskari Heikinheimo, Sharon Cameron, Kristina Gemzell-Danielsson","doi":"10.1055/s-0042-1760117","DOIUrl":"https://doi.org/10.1055/s-0042-1760117","url":null,"abstract":"<p><p>\"Very early medical abortion\" (VEMA) refers to medical abortion (with mifepristone and misoprostol) before intrauterine pregnancy is visualized on ultrasound. Our aim is to present the current evidence on efficacy, safety (focused on ectopic pregnancies), and how to assess treatment success of VEMA. We conducted a systematic review of studies reporting outcomes of VEMA. The field is small and so our objective was to map all relevant literature, without conducting meta-analysis. We searched PubMed, Medline, and Embase on April 19, 2022. We conducted a narrative synthesis of the evidence. A total of 373 articles were identified. Six articles (representing four observational and one pilot trial) were included in the final review. Across all included studies, treatment efficacy ranged between 91 and 100%. Prevalence of ectopic pregnancy was low and very few cases (<i>n</i> = 2) of ruptures were reported. Most studies used serial serum human chorionic gonadotrophin (s-hCG) levels to determine success of abortion; one study used low sensitivity urine hCG. From the available evidence, VEMA appears to be efficacious and does not appear to cause harm to ectopic pregnancies. Treatment can be assessed with pre- and postabortion s-hCG. Good quality, randomized controlled trial evidence is needed to best inform practice.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"40 5-06","pages":"258-263"},"PeriodicalIF":2.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10673657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Edwina Dorney, Geraldine Barrett, Jennifer Hall, Kirsten I Black
Understanding pregnancy intention is an important public health measure that captures the ability of individuals to access information, resources, and services needed to plan the timing and spacing of pregnancies. Pregnancy intention is a complex construct impacted by social, emotional, financial, cultural, and contextual factors. In this review, we will examine the range of available tools for individuals and populations to evaluate pregnancy intention, the timing of the tools in relation to pregnancy, their interpretation, and use for policy and practice. Traditionally, pregnancy intention was only assessed in population health surveys; however, more sophisticated tools and measures have been developed. These tools can be used at several time points: before pregnancy, during pregnancy, or after the pregnancy has ended. It is important to appreciate the varied contexts globally for women and their partners when assessing pregnancy intention, and the ability of a given tool to capture this when used retrospectively or prospectively. These tools can inform targeted delivery of services for a person or couple before, during, and after pregnancy. This knowledge can inform strategies at an individual, community, and population level as an indicator of access to sexual and reproductive health information and knowledge and uptake of preconception health.
{"title":"Measures of Pregnancy Intention: Why Use Them and What Do They Tell Us?","authors":"Edwina Dorney, Geraldine Barrett, Jennifer Hall, Kirsten I Black","doi":"10.1055/s-0042-1760118","DOIUrl":"https://doi.org/10.1055/s-0042-1760118","url":null,"abstract":"<p><p>Understanding pregnancy intention is an important public health measure that captures the ability of individuals to access information, resources, and services needed to plan the timing and spacing of pregnancies. Pregnancy intention is a complex construct impacted by social, emotional, financial, cultural, and contextual factors. In this review, we will examine the range of available tools for individuals and populations to evaluate pregnancy intention, the timing of the tools in relation to pregnancy, their interpretation, and use for policy and practice. Traditionally, pregnancy intention was only assessed in population health surveys; however, more sophisticated tools and measures have been developed. These tools can be used at several time points: before pregnancy, during pregnancy, or after the pregnancy has ended. It is important to appreciate the varied contexts globally for women and their partners when assessing pregnancy intention, and the ability of a given tool to capture this when used retrospectively or prospectively. These tools can inform targeted delivery of services for a person or couple before, during, and after pregnancy. This knowledge can inform strategies at an individual, community, and population level as an indicator of access to sexual and reproductive health information and knowledge and uptake of preconception health.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"40 5-06","pages":"229-234"},"PeriodicalIF":2.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10683177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sexual activity and fertility can resume shortly after childbirth, but there are barriers to contraceptive access in the postpartum period. Unintended pregnancy and short interpregnancy intervals (of less than one year) can increase the risk of obstetric and neonatal complications. The antenatal period presents an opportunity to discuss contraceptive options, many of which can be safely initiated immediately after childbirth. Successful delivery of a postpartum contraception program requires an adequate number of maternity staff trained to provide the full range of methods.
{"title":"Improving Access to and Quality of Postpartum Contraception Provision.","authors":"Michelle Cooper, Sharon Cameron","doi":"10.1055/s-0042-1758114","DOIUrl":"https://doi.org/10.1055/s-0042-1758114","url":null,"abstract":"<p><p>Sexual activity and fertility can resume shortly after childbirth, but there are barriers to contraceptive access in the postpartum period. Unintended pregnancy and short interpregnancy intervals (of less than one year) can increase the risk of obstetric and neonatal complications. The antenatal period presents an opportunity to discuss contraceptive options, many of which can be safely initiated immediately after childbirth. Successful delivery of a postpartum contraception program requires an adequate number of maternity staff trained to provide the full range of methods.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"40 5-06","pages":"235-239"},"PeriodicalIF":2.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10673658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Contraception, preconception care, and abortion are integral and intertwined aspects of women’s reproductive health.We know that nearly half of all pregnancies worldwide are unintended, which can have significant consequences for women, girls, and society more broadly.1 Over 60% of unintended pregnancies, and almost 30% of all pregnancies, end in abortion (noting that nearly half of all abortions performed globally are unsafe).1 Most unintended pregnancies can be attributed to nonor incorrect use of contraception or contraceptive failure,2,3 yet there are approximately 257 million women globally who want to avoid pregnancy but are not using a safe,modernmethod of contraception due to lack of access.1 It is therefore imperative that women are able to access effective methods of contraception, support in pregnancy planning, and abortion care so they can achieve their reproductive life goals. In this issue, we address these aspects of reproductive health. We examine the tools available to evaluate pregnancy intention and the implications of their use for policy and practice. Understanding pregnancy intentions can help women (and the clinicians supporting them)make decisions about contraception to suit their needs. We explore the opportunities for increasing access to effective contraception, using examples from the Australian context, and consider how to improve access to and quality of postpartum contraception provision. We present a common clinical scenario, that of obesity amongwomen of reproductive age seeking contraception and discuss the considerations and approaches for facilitating provision of inclusive contraceptive care for this population group. This includes a review of current evidence on method-specific advantages and disadvantages for people with obesity to guide practice and policy. Finally, we present several articles relating to medical abortion, including a systematic review relating to another common clinical scenario, that of very early medical abortion (VEMA), to report thecurrentevidenceonefficacy, safety, and treatment success of VEMA. We conclude with two case studies from Canada: one focused on access to abortion care for incarcerated people and another on the deregulation ofmedical abortion to support access to safe, early abortion care in primary care settings. The articles in this issue will be of interest to clinicians as well as public health–focused researchers and decision-makers. The issue provides an overviewof current global challenges in reproductive health and provides reviews of the evidence to guide clinical practice and public health responses to key issues relating to pregnancy intention, contraception, and abortion care.
{"title":"Sexual and Reproductive Health.","authors":"Danielle Mazza, Jessica R Botfield","doi":"10.1055/s-0042-1759553","DOIUrl":"https://doi.org/10.1055/s-0042-1759553","url":null,"abstract":"Contraception, preconception care, and abortion are integral and intertwined aspects of women’s reproductive health.We know that nearly half of all pregnancies worldwide are unintended, which can have significant consequences for women, girls, and society more broadly.1 Over 60% of unintended pregnancies, and almost 30% of all pregnancies, end in abortion (noting that nearly half of all abortions performed globally are unsafe).1 Most unintended pregnancies can be attributed to nonor incorrect use of contraception or contraceptive failure,2,3 yet there are approximately 257 million women globally who want to avoid pregnancy but are not using a safe,modernmethod of contraception due to lack of access.1 It is therefore imperative that women are able to access effective methods of contraception, support in pregnancy planning, and abortion care so they can achieve their reproductive life goals. In this issue, we address these aspects of reproductive health. We examine the tools available to evaluate pregnancy intention and the implications of their use for policy and practice. Understanding pregnancy intentions can help women (and the clinicians supporting them)make decisions about contraception to suit their needs. We explore the opportunities for increasing access to effective contraception, using examples from the Australian context, and consider how to improve access to and quality of postpartum contraception provision. We present a common clinical scenario, that of obesity amongwomen of reproductive age seeking contraception and discuss the considerations and approaches for facilitating provision of inclusive contraceptive care for this population group. This includes a review of current evidence on method-specific advantages and disadvantages for people with obesity to guide practice and policy. Finally, we present several articles relating to medical abortion, including a systematic review relating to another common clinical scenario, that of very early medical abortion (VEMA), to report thecurrentevidenceonefficacy, safety, and treatment success of VEMA. We conclude with two case studies from Canada: one focused on access to abortion care for incarcerated people and another on the deregulation ofmedical abortion to support access to safe, early abortion care in primary care settings. The articles in this issue will be of interest to clinicians as well as public health–focused researchers and decision-makers. The issue provides an overviewof current global challenges in reproductive health and provides reviews of the evidence to guide clinical practice and public health responses to key issues relating to pregnancy intention, contraception, and abortion care.","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"40 5-06","pages":"227-228"},"PeriodicalIF":2.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10683174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarah B Munro, Sheila Dunn, Edith R Guilbert, Wendy V Norman
Mifepristone medication abortion was first approved in China and France more than 30 years ago and is now used in more than 60 countries worldwide. It is a highly safe and effective method that has the potential to increase population access to abortion in early pregnancy, closer to home. In both Canada and the United States, the initial regulations for distribution, prescribing, and dispensing of mifepristone were highly restricted. However, in Canada, where mifepristone was made available in 2017, most restrictions on the medication were removed in the first year of its availability. The Canadian regulation of mifepristone as a normal prescription makes access possible in community primary care through a physician or nurse practitioner prescription, which any pharmacist can dispense. In this approach, people decide when and where to take their medication. We explore how policy-maker-engaged research advanced reproductive health policy and facilitated this rapid change in Canada. We discuss the implications of these policy advances for self-management of abortion and demonstrate how in Canada patients "self-manage" components of the abortion process within a supportive health care system.
{"title":"Advancing Reproductive Health through Policy-Engaged Research in Abortion Care.","authors":"Sarah B Munro, Sheila Dunn, Edith R Guilbert, Wendy V Norman","doi":"10.1055/s-0042-1760213","DOIUrl":"https://doi.org/10.1055/s-0042-1760213","url":null,"abstract":"<p><p>Mifepristone medication abortion was first approved in China and France more than 30 years ago and is now used in more than 60 countries worldwide. It is a highly safe and effective method that has the potential to increase population access to abortion in early pregnancy, closer to home. In both Canada and the United States, the initial regulations for distribution, prescribing, and dispensing of mifepristone were highly restricted. However, in Canada, where mifepristone was made available in 2017, most restrictions on the medication were removed in the first year of its availability. The Canadian regulation of mifepristone as a normal prescription makes access possible in community primary care through a physician or nurse practitioner prescription, which any pharmacist can dispense. In this approach, people decide when and where to take their medication. We explore how policy-maker-engaged research advanced reproductive health policy and facilitated this rapid change in Canada. We discuss the implications of these policy advances for self-management of abortion and demonstrate how in Canada patients \"self-manage\" components of the abortion process within a supportive health care system.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"40 5-06","pages":"268-276"},"PeriodicalIF":2.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10683176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Maya I Ragavan, Romina L Barral, Kimberly A Randell
Adolescent relationship abuse (ARA) is a significant public health issue that includes physical, sexual, psychological and cyber abuse, reproductive coercion, and/or sexual exploitation within an intimate relationship in which one or both partners is a minor. ARA is associated with numerous negative outcomes that include all domains of health. Many negative outcomes of ARA are related to reproductive and sexual health (RSH); thus, reproductive health care providers must be equipped to recognize and address ARA. This article will review the epidemiology and outcomes of ARA, followed by a discussion of means to robustly address ARA in health care settings. We recommend a strengths-based approach that promotes healthy adolescent relationships, connects adolescents experiencing ARA to harm reduction resources, and equips adolescents to serve as a resource for their peers.
{"title":"Addressing Adolescent Relationship Abuse in the Context of Reproductive Health Care.","authors":"Maya I Ragavan, Romina L Barral, Kimberly A Randell","doi":"10.1055/s-0041-1741519","DOIUrl":"https://doi.org/10.1055/s-0041-1741519","url":null,"abstract":"<p><p>Adolescent relationship abuse (ARA) is a significant public health issue that includes physical, sexual, psychological and cyber abuse, reproductive coercion, and/or sexual exploitation within an intimate relationship in which one or both partners is a minor. ARA is associated with numerous negative outcomes that include all domains of health. Many negative outcomes of ARA are related to reproductive and sexual health (RSH); thus, reproductive health care providers must be equipped to recognize and address ARA. This article will review the epidemiology and outcomes of ARA, followed by a discussion of means to robustly address ARA in health care settings. We recommend a strengths-based approach that promotes healthy adolescent relationships, connects adolescents experiencing ARA to harm reduction resources, and equips adolescents to serve as a resource for their peers.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"40 1-02","pages":"146-154"},"PeriodicalIF":2.7,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885502/pdf/nihms-1865102.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9374321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01Epub Date: 2021-07-14DOI: 10.1055/s-0041-1732375
Anne Flem Jacobsen, Per Morten Sandset
Assisted reproductive therapy (ART) increases the risk of venous thrombosis (VT) by 2- to 4-fold, whereas pregnancy increases the risk by 5- to 10-fold. Women with a history of VT undergoing ART are often suggested thromboprophylaxis. The literature is scarce and international guidelines are lacking. We made a review of the literature and base our suggestions primarily on expert opinions. We suggest women with a prior VT to use low-molecular-weight heparin as thromboprophylaxis starting from ovarian stimulation, throughout pregnancy, and 6 weeks postpartum. Assessment of VT risk should be done prior to ART. Adjustment of treatment to minimize the thrombotic risk, such as preventing ovarian hyperstimulation syndrome, single-embryo transfer, cryopreservation, and transfer of frozen embryos instead of fresh embryo in high-risk women, is suggested. Women with previous arterial thrombosis should continue aspirin during ART treatment, pregnancy, and postpartum.
{"title":"Prior Thromboembolic Disease and Assisted Reproductive Therapy.","authors":"Anne Flem Jacobsen, Per Morten Sandset","doi":"10.1055/s-0041-1732375","DOIUrl":"https://doi.org/10.1055/s-0041-1732375","url":null,"abstract":"<p><p>Assisted reproductive therapy (ART) increases the risk of venous thrombosis (VT) by 2- to 4-fold, whereas pregnancy increases the risk by 5- to 10-fold. Women with a history of VT undergoing ART are often suggested thromboprophylaxis. The literature is scarce and international guidelines are lacking. We made a review of the literature and base our suggestions primarily on expert opinions. We suggest women with a prior VT to use low-molecular-weight heparin as thromboprophylaxis starting from ovarian stimulation, throughout pregnancy, and 6 weeks postpartum. Assessment of VT risk should be done prior to ART. Adjustment of treatment to minimize the thrombotic risk, such as preventing ovarian hyperstimulation syndrome, single-embryo transfer, cryopreservation, and transfer of frozen embryos instead of fresh embryo in high-risk women, is suggested. Women with previous arterial thrombosis should continue aspirin during ART treatment, pregnancy, and postpartum.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"39 5-06","pages":"180-185"},"PeriodicalIF":2.7,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39183508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01Epub Date: 2022-01-10DOI: 10.1055/s-0041-1742149
Patricia Fadon, Eleanor Gallegos, Salonika Jalota, Lourdes Muriel, Cesar Diaz-Garcia
Time-lapse systems have quickly become a common feature of in vitro fertilization laboratories all over the world. Since being introduced over a decade ago, the alleged benefits of time-lapse technology have continued to grow, from undisturbed culture conditions and round the clock, noninvasive observations to more recent computer-assisted selection of embryos through the development of algorithms. Despite the global uptake of time-lapse technology, its real impact on clinical outcomes is still controversial. This review aims to explore the different features offered by time-lapse technology, discussing incubation, algorithms, artificial intelligence and the regulation of nonessential treatment interventions, while assessing evidence on whether any benefit is offered over conventional technology.
{"title":"Time-Lapse Systems: A Comprehensive Analysis on Effectiveness.","authors":"Patricia Fadon, Eleanor Gallegos, Salonika Jalota, Lourdes Muriel, Cesar Diaz-Garcia","doi":"10.1055/s-0041-1742149","DOIUrl":"https://doi.org/10.1055/s-0041-1742149","url":null,"abstract":"<p><p>Time-lapse systems have quickly become a common feature of in vitro fertilization laboratories all over the world. Since being introduced over a decade ago, the alleged benefits of time-lapse technology have continued to grow, from undisturbed culture conditions and round the clock, noninvasive observations to more recent computer-assisted selection of embryos through the development of algorithms. Despite the global uptake of time-lapse technology, its real impact on clinical outcomes is still controversial. This review aims to explore the different features offered by time-lapse technology, discussing incubation, algorithms, artificial intelligence and the regulation of nonessential treatment interventions, while assessing evidence on whether any benefit is offered over conventional technology.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"39 5-06","pages":"e12-e18"},"PeriodicalIF":2.7,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39804761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-01Epub Date: 2021-10-13DOI: 10.1055/s-0041-1736492
Paolo Emanuele Levi-Setti, Noemi Di Segni, Clara Gargasole, Camilla Ronchetti, Federico Cirillo
Ovarian hyperstimulation syndrome (OHSS) is a severe complication of controlled ovarian stimulation (COS). Pathogenesis of the disease is based on massive transudation of protein-rich fluid from the vascular compartment into the peritoneal, pleural and pericardial spaces, with a variable picture of clinical manifestations depending on its severity. Nowadays OHSS can easily be avoided by several prevention methods, ranging from identification of high-risk patients, choice of a correct protocol stimulation, trigger with gonadotropin-releasing hormone (GnRH) agonists or, finally, the freeze-all strategy. When OHSS occurs, it can usually be managed as outpatient care. Only if severe/critical cases are diagnosed hospitalization is necessary for appropriate rehydration, monitoring of fluid balance and eventual drainage of ascitic fluid. One of the most dangerous complications of OHSS is venous thromboembolism (VTE). Thromboprophylaxis has shown to be cost effective and widely used, while there are controversies regarding the usage of low dose aspirin (LDA) as a preventive measure.
{"title":"Ovarian Hyperstimulation: Diagnosis, Prevention, and Management.","authors":"Paolo Emanuele Levi-Setti, Noemi Di Segni, Clara Gargasole, Camilla Ronchetti, Federico Cirillo","doi":"10.1055/s-0041-1736492","DOIUrl":"https://doi.org/10.1055/s-0041-1736492","url":null,"abstract":"<p><p>Ovarian hyperstimulation syndrome (OHSS) is a severe complication of controlled ovarian stimulation (COS). Pathogenesis of the disease is based on massive transudation of protein-rich fluid from the vascular compartment into the peritoneal, pleural and pericardial spaces, with a variable picture of clinical manifestations depending on its severity. Nowadays OHSS can easily be avoided by several prevention methods, ranging from identification of high-risk patients, choice of a correct protocol stimulation, trigger with gonadotropin-releasing hormone (GnRH) agonists or, finally, the freeze-all strategy. When OHSS occurs, it can usually be managed as outpatient care. Only if severe/critical cases are diagnosed hospitalization is necessary for appropriate rehydration, monitoring of fluid balance and eventual drainage of ascitic fluid. One of the most dangerous complications of OHSS is venous thromboembolism (VTE). Thromboprophylaxis has shown to be cost effective and widely used, while there are controversies regarding the usage of low dose aspirin (LDA) as a preventive measure.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"39 5-06","pages":"170-179"},"PeriodicalIF":2.7,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39514176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}